Five Oceans Advisors Acquires New Holdings in GSK plc (NYSE:GSK)

Five Oceans Advisors bought a new position in GSK plc (NYSE:GSK) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 5,683 shares of the pharmaceutical company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dorsey & Whitney Trust CO LLC raised its holdings in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after purchasing an additional 278 shares in the last quarter. Northwest Bank & Trust Co boosted its stake in shares of GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock valued at $765,000 after purchasing an additional 289 shares in the last quarter. GC Wealth Management RIA LLC increased its position in shares of GSK by 2.6% during the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after buying an additional 353 shares during the period. Rhumbline Advisers raised its stake in GSK by 2.1% in the first quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock worth $713,000 after buying an additional 386 shares in the last quarter. Finally, Jacobi Capital Management LLC lifted its holdings in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after buying an additional 389 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GSK. BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price on the stock. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Berenberg Bank reiterated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, GSK has an average rating of “Hold” and an average price target of $37.38.

GSK Price Performance

GSK stock opened at $40.50 on Tuesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a 50 day moving average price of $38.22 and a 200-day moving average price of $36.73. GSK plc has a 52-week low of $31.72 and a 52-week high of $44.67. The firm has a market capitalization of $83.00 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 1.12 and a beta of 0.52.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the company earned $0.43 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.16%. GSK’s dividend payout ratio (DPR) is presently 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.